GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Rize Oncology Inc (XCNQ:RIZE) » Definitions » Tax Expense

Rize Oncology (XCNQ:RIZE) Tax Expense : C$0.00 Mil (TTM As of Sep. 2024)


View and export this data going back to 2022. Start your Free Trial

What is Rize Oncology Tax Expense?

Rize Oncology's tax expense for the months ended in Sep. 2024 was C$0.00 Mil. Its tax expense for the trailing twelve months (TTM) ended in Sep. 2024 was C$0.00 Mil.


Rize Oncology Tax Expense Historical Data

The historical data trend for Rize Oncology's Tax Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Rize Oncology Tax Expense Chart

Rize Oncology Annual Data
Trend Dec20 Dec21 Dec22 Dec23
Tax Expense
- - - -

Rize Oncology Quarterly Data
Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
Tax Expense Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Rize Oncology Tax Expense Calculation

Tax paid by the company. It is computed in by multiplying the income before tax number, as reported to shareholders, by the appropriate tax rate. In reality, the computation is typically considerably more complex due to things such as expenses considered not deductible by taxing authorities ("add backs"), the range of tax rates applicable to various levels of income, different tax rates in different jurisdictions, multiple layers of tax on income, and other issues.

Tax Expense for the trailing twelve months (TTM) ended in Sep. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was C$0.00 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Rize Oncology  (XCNQ:RIZE) Tax Expense Explanation

In the long run, income before tax and taxable income will likely be more similar than they are in any given period. If the one is less in earlier years, then it will be greater in later years. Deferred taxes will reverse themselves in the long run and in total will zero out, unless there is something like a change in tax rates in the intervening period. A deferred tax payable results from a tax break in the early years and will reverse itself in later years; a deferred tax receivable results from more taxes being paid in early years than the tax expense reported to shareholders and will again reverse itself in later years. The deferred tax amount is computed by estimating the amount and the timing of the reversal and multiplying that by the appropriate tax rates.


Rize Oncology Tax Expense Related Terms

Thank you for viewing the detailed overview of Rize Oncology's Tax Expense provided by GuruFocus.com. Please click on the following links to see related term pages.


Rize Oncology Business Description

Traded in Other Exchanges
N/A
Address
301-1665 Ellis Street, c/o Pushor Mitchell LLP, Kelowna, BC, CAN, X1X 1X1
Rize Oncology Inc is is a pharmaceutical company. The company is engaged in oncology, particularly soft tissue sarcoma, introduced by the recent exclusive licensing of STS-201, delivering small molecule targeting soft tissue sarcoma and other cancers.
Executives
William James Garner 10% Security Holder, Director

Rize Oncology Headlines

No Headlines